Trial DesignApixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale
Section snippets
Warfarin
Warfarin, a vitamin K antagonist (VKA), reduces the risk of stroke by approximately 62%6; however, VKAs have major limitations and are underused in clinical practice.7 Patients are frequently outside the optimal target anticoagulation range when VKAs are prescribed, exposing them to the risk of thrombosis or bleeding.8, 9 Clinical trial data show that among patients receiving warfarin or other VKAs, even in the highly structured setting of a trial, the international normalized ratio (INR) is
Apixaban
Factor Xa occupies a pivotal role in the clotting cascade because it promotes conversion of prothrombin to thrombin. Developed as an anticoagulant agent, apixaban is an orally active selective inhibitor of the coagulation factor Xa. The direct mechanism of this drug does not require the presence of antithrombin. It has a predominantly nonrenal (75%) clearance and a half-life around 12 hours in healthy volunteers. The effect is independent of vitamin K intake, and with the exception of strong
Primary objective
The primary objective of this study is to determine whether apixaban is noninferior to warfarin (INR target range 2.0-3.0) at reducing the combined outcome of stroke (ischemic or hemorrhagic) and systemic embolism in subjects with AF and at least 1 additional risk factor for stroke.
Secondary objectives
The key secondary objectives are to determine if apixaban is superior to warfarin for the combined endpoint of stroke (ischemic or hemorrhagic) and systemic embolism, and for all-cause death. These will be tested
Study population
In this double-blind study, we have randomized 18,206 patients with AF from over 1,000 centers in about 40 countries. Eligible subjects were randomly assigned in a 1:1 ratio to receive either apixaban or warfarin titrated to a target INR range of 2.0 to 3.0. Both warfarin-naïve and warfarin-experienced patients are being recruited, with a special emphasis on the former. Our aim is for 40% of patients to be warfarin naïve. The inclusion and exclusion criteria are summarized in Table I.
Randomization and study drug
Subjects who were on warfarin before randomization discontinued the drug 72 hours before randomization and were not dosed with study drug until the INR was <2.0. Randomization is stratified by investigative site and prior warfarin use status (experienced or naïve). Patients are classified as warfarin naïve if they have never used warfarin (or other VKAs) or if they have used it for ≤30 consecutive days. Otherwise, patients are considered warfarin experienced.
To maintain blinding, study
Study design and duration
The trial is event driven, thus, the number of subjects required and length of treatment were estimated based on event rates in similar trials. The final duration of the trial will be determined by the time required to accrue at least 448 primary efficacy events (see statistical methods). All subjects will be followed from randomization until the study end date.
The study includes a screening period of up to 14 days. Subjects with AF and at least ≥1 risk factors for stroke will be evaluated for
Efficacy outcomes
The primary efficacy outcome is the time to first occurrence of stroke (ischemic or hemorrhagic) or systemic embolism.
In this study, stroke is defined as a nontraumatic abrupt onset of a focal neurologic deficit lasting at least 24 hours. A retinal ischemic event (embolism or thrombosis) will be considered a stroke. A cerebral imaging study (computed tomographic scan or magnetic resonance imaging) is recommended for all suspected strokes. Strokes will be classified as ischemic, ischemic with
Clinical Events Committee adjudication
An independent, blinded, clinical events committee (CEC) adjudicates all suspected hemorrhagic and non-hemorrhagic strokes, TIAs, systemic emboli, major and clinically relevant non-major bleeding, myocardial infarction, and cause of death.
Using prespecified event definitions and agreed upon event adjudication criteria, the CEC adjudicates suspected events based on the preponderance of the evidence and the clinical knowledge and experience of the physician reviewers. Event adjudication in
Statistical analysis and sample size calculation
A meta-analysis of 6 AF studies estimated a relative reduction in the risk of stroke or systemic thromboembolism of 62% for warfarin versus placebo.6 Based on historical trials, the primary noninferiority hypothesis of ARISTOTLE is that apixaban will preserve at least 50% of the benefit of warfarin in preventing stroke and systemic embolism. This gives an upper CI of 1.88 of the apixaban versus warfarin relative risk (Figure 2A). To be more certain that apixaban is noninferior to warfarin based
Pharmacokinetic biomarkers
The main objectives of the biomarker and genetic substudy program are to correlate genetic polymorphisms and levels of biomarkers with clinical outcomes, to improve risk stratification for stroke among patients with AF, and to relate the effects of apixaban and warfarin to these disease biomarkers. Several biomarkers will be analyzed at baseline for as many of the 18,206 patients as possible (Table II), and a second blood sample will be collected for approximately 5,000 patients at 2 months.
Organizational structure
The ARISTOTLE trial is led by an academic steering committee composed of 2 cochairs, national coordinators from each participating country, and a representative from the trial sponsor. This committee provides scientific direction and input, addresses policy issues regarding the protocol, and meets periodically to assess the trial progress.
The ARISTOTLE executive committee, composed of a subset of senior leaders from the steering committee, is responsible for evaluating the progress and safety
Discussion
Atrial fibrillation is a very common arrhythmia and is associated with an increased risk of mortality and morbidity, particularly stroke, which is the third most common cause of death in developed countries and the leading cause of serious long-term disability worldwide.28
The ACTIVE-W study included 6,706 patients with AF and at least ≥1 risk factors for stroke.18 ACTIVE-W was designed to compare oral anticoagulation therapy with aspirin plus clopidogrel for prevention of vascular events in
Conclusion
In conclusion, the ARISTOTLE trial will answer many important questions related to stroke prevention in AF. Most importantly, it will compare apixaban with warfarin for stroke prevention in a wide range of patients with AF. It will provide information about the efficacy of apixaban both in warfarin-experienced and warfarin-naïve patients. Finally, it will generate a better understanding of this common disease and the risks of stroke and bleeding based on large scale substudies on genetic and
References (35)
- et al.
Effect of study setting on anticoagulation control: a systematic review and metaregression
Chest
(2006) - et al.
Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest
(2008) Warfarin interaction with herbal drugs and food
Int J Cardiol
(2007)- et al.
Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies
J Thromb Haemost
(2008) - et al.
1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1, 1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa
Bioorg Med Chem Lett
(2006) - et al.
The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement
J Thromb Haemost
(2007) - et al.
Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention
Circulation
(2003) - et al.
Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence
Circulation
(2006) - et al.
Impact of atrial fibrillation on the risk of death: the Framingham Heart Study
Circulation
(1998) - et al.
Probability of stroke: a risk profile from the Framingham Study
Stroke
(1991)
Present treatment options for atrial fibrillation
Postgrad Med J
Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis
Ann Intern Med
Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation
Circulation
Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis
Am Heart J
Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review
Circulation Cardiovascular Quality and Outcomes
Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial
JAMA
Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial
Lancet
Cited by (390)
The prothrombotic tendency of metabolic-associated fatty liver disease
2023, Journal of Thrombosis and HaemostasisIndividual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC‐AF risk scores
2023, American Heart JournalSafety and efficacy of direct oral anticoagulants in comparison with warfarin across different BMI ranges: A systematic review and meta-analysis
2022, Annals of Medicine and Surgery
RCT reg no. NCT00412984.